deltatrials
Completed PHASE2 NCT00010439

Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis

A Non-Randomized, Open-Label, Prospective, Non-Controlled, 12-Month Clinical Trial to Determine the Effects of Alendronate 35 or 70 mg/Week Depending Upon Body Weight, in Children and Adolescent With IJO

Sponsor: Medical University of South Carolina

Conditions Osteoporosis
Interventions Alendronate
Updated 9 times since 2017 Last updated: Oct 21, 2010 Started: Sep 30, 2000 Primary completion: Oct 31, 2003 Completion: Nov 30, 2008

Listed as NCT00010439, this PHASE2 trial focuses on Osteoporosis and remains completed. Sponsored by Medical University of South Carolina, it has been updated 9 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Jun 2022 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Sep 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Medical University of South Carolina
  • Merck Sharp & Dohme LLC
Data source: Medical University of South Carolina

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Charleston, United States